Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced ER+/HER2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT01238952
What this trial is testing

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

Who this might be right for
Advanced Solid TumorsMetastatic Triple Negative Breast Cancer
Nippon Kayaku Co., Ltd. 4
Testing effectiveness (Phase 2)Looking for participantsNCT07002177
What this trial is testing

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd. 196
Large-scale testing (Phase 3)Study completedNCT03176238
What this trial is testing

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Post Menopausal Breast Cancer
Novartis Pharmaceuticals 235
Early research (Phase 1)Active Not RecruitingNCT05293964
What this trial is testing

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 214
Testing effectiveness (Phase 2)Ended earlyNCT05618613
What this trial is testing

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Context Therapeutics Inc. 4
Early research (Phase 1)Ended earlyNCT05080842
What this trial is testing

AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 21
Testing effectiveness (Phase 2)Study completedNCT03822468
What this trial is testing

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 376
Early research (Phase 1)Study completedNCT02499146
What this trial is testing

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 26
Testing effectiveness (Phase 2)WithdrawnNCT03841747
What this trial is testing

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Queen Mary University of London
Not applicableStudy completedNCT03195192
What this trial is testing

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Side-Out Foundation 28
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Early research (Phase 1)Active Not RecruitingNCT03616587
What this trial is testing

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 396
Large-scale testing (Phase 3)UnknownNCT05985187
What this trial is testing

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

Who this might be right for
HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 412
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Testing effectiveness (Phase 2)Ended earlyNCT00206492
What this trial is testing

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Who this might be right for
Breast Cancer
Baylor Breast Care Center 3
Early research (Phase 1)Study completedNCT01482156
What this trial is testing

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsMetastatic Breast CancerMetastatic Renal Cell Carcinoma
Novartis Pharmaceuticals 46
Testing effectiveness (Phase 2)UnknownNCT03772353
What this trial is testing

Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 59
Testing effectiveness (Phase 2)Ended earlyNCT00674557
What this trial is testing

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

Who this might be right for
Breast Cancer
Cancer Research UK 111
Not applicableUnknownNCT02875951
What this trial is testing

Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer

Who this might be right for
ER Positive, HER2 Negative Breast Cancer Neoplasms
KU Leuven 100
Testing effectiveness (Phase 2)Ended earlyNCT02569801
What this trial is testing

GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

Who this might be right for
Breast Cancer
Genentech, Inc. 71
Next Page